News

Foam treatment rapidly relieves itch and clears stubborn scalp psoriasis lesions
Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...
J&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist
Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...
Johnson & Johnson: Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...
Stocktwits on MSN45m
Johnson & Johnson’s Psoriasis Drug Meets Goal In Late Stage Study: Retail Yet To Be Impressed
Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...
J&J's skin disease drug meets main goal in late-stage study
(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear ...
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements
Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that ...